# Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Canonical URL: https://biopharmsignal.com/news/RIGL/rigel-enters-exclusive-global-licensing-agreement-for-veppanutm-vepdegestrant-an-oral-protac-for-the-treatment-of-2l-er-her2-esr1m-advanced-or-metastatic-breast-cancer
Ticker: RIGL
Company: Rigel Pharmaceuticals
Source: Rigel Pharmaceuticals
Published: 2026-05-12 11:00 EST
Original Source URL: https://www.rigel.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-01 12:05 EST — [Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/RIGL/rigel-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-c2f47409) — Source: Rigel Pharmaceuticals
- 2026-06-16 20:01 EST — [Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)](https://biopharmsignal.com/news/RIGL/rigel-announces-closing-of-licensing-agreement-for-veppanu-vepdegestrant-31709183) — Source: Rigel Pharmaceuticals
- 2026-05-27 12:05 EST — [Rigel to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference) — Source: Rigel Pharmaceuticals
- 2026-05-21 21:17 EST — [Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress](https://biopharmsignal.com/news/RIGL/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress) — Source: Rigel Pharmaceuticals
- 2026-05-14 12:05 EST — [Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-2026-rbc-capital-markets-global-healthcare-conference) — Source: Rigel Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)